In this study, we demonstrated in mouse tumor models the selective capacity of low dose CA-4 or eribulin to induce tumor pericyte phenotype switching from a highly proliferative to a contractile state by activating RhoA kinase. The gene discussed is CA4; the disease is neoplasm.